Skip to main content

Hydrodissection

Hydrodissection, the submucosal injection of fluid into the vaginal wall to hydraulically separate the vaginal epithelium from the underlying fibromuscular layer, is a commonly used adjunct in vaginal prolapse surgery, with variation in technique and use.[1][2] It serves two purposes at once: it creates a defined dissection plane (between the epithelium and the pubocervical connective tissue anteriorly and the rectovaginal septum posteriorly), and, when a vasoconstrictor is added, it provides tamponade and vasoconstriction that reduce intraoperative blood loss. The 2025 Cochrane review found limited perioperative evidence and did not establish clinically meaningful benefit for most interventions.[1]

Principle and Purpose​

The injected fluid balloons the submucosa and visually delineates the cleavage plane, so dissection follows hydraulics rather than blind sharp cutting. Adding a vasoconstrictor compresses and constricts the submucosal vessels along that plane. The two goals are partly independent: plain saline can separate the plane; vasoconstrictors may modestly reduce blood loss but introduce systemic cardiovascular risk. Neither approach guarantees a correct plane or improved long-term repair.[1][2]

Technique by Procedure​

Anterior colporrhaphy​

After an Allis clamp is placed on the anterior vaginal wall, solution is injected submucosally along the planned incision and laterally into the vesicovaginal space until the tissue balloons and the plane between epithelium and pubocervical connective tissue is visible. A midline vertical incision is carried through the distended epithelium, then dissection is limited to the extent needed for the planned repair. A routine midline colporrhaphy does not require dissection to the arcus tendineus fascia pelvis.[2] A randomized trial in 46 women undergoing primary anterior colporrhaphy reported a smaller hemoglobin decrease with hydrodissection (0.66 versus 1.21 g/dL, p = 0.05). Loose connective tissue was identified in trimmed vaginal tissue in 3 women after hydrodissection versus 6 without hydrodissection (p = 0.46), a histological surrogate; later repair outcomes were not assessed.[2]

Posterior colporrhaphy​

Subepithelial infiltration can facilitate separation of vaginal epithelium from the supporting fibromuscular layer while protecting the rectum. Routine posterior colporrhaphy does not require full-thickness posterior-wall dissection or opening the pararectal space to the sacrospinous ligament; that exposure belongs to separately indicated procedures.

Vaginal hysterectomy​

A pericervical or intracervical circumferential injection before the initial circumferential incision distends the vesicovaginal and rectovaginal planes and eases entry into the anterior and posterior cul-de-sacs. A hysterectomy meta-analysis of 7 RCTs (455 patients; five vaginal and two abdominal trials) found vasopressin cut estimated blood loss by a mean of 119.85 mL (95% CI −177.55 to −62.14; six trials reporting this outcome).[6] An RCT of 8 units intracervical vasopressin reduced blood loss to about 145 versus 266 mL (p = 0.022) but raised mean blood pressure more at 5 minutes and increased postoperative morphine use.[6][7]

Colpocleisis (LeFort and total)​

In Raju and colleagues’ LeFort colpocleisis technique, lidocaine with epinephrine hydrodissection separates the epithelium from the underlying fibromuscular layer before anterior and posterior rectangular patches are excised and plicated.[3] In Linder and colleagues’ total colpocleisis technique, the same injectate precedes circumferential, quadrant-based epithelial removal; serial purse-string sutures then reduce the prolapse.[4]

Historical vaginal mesh procedures​

Published transvaginal POP-mesh techniques describe normal saline infiltration before the vaginal-wall incision in transobturator or transgluteal and single-incision systems; the described dissection depends on the device.[22]

Injectate Agents and Dilutions​

AgentTypical dilution / doseEffect on blood lossKey consideration
Normal saline aloneVolume tailored to tissue and procedureSmall-trial blood-loss signalBaseline; plane separation without vasoconstriction[1][2]
Epinephrine-containing injectate1:200,000 (5 µg/mL) was used with bupivacaine in one vaginal-hysterectomy trialDirect vaginal evidence comparing epinephrine alone with saline is limitedAccount for cardiovascular effects and total dose[9][19]
Ornipressin (Por-8)5 IU in 100 mL saline (0.05 IU/mL); ~80 mL/compartmentMedian 35 vs 81 mL saline (p = 0.03)No measured BP/pulse difference in one small trial; rare-event safety not established[5]
VasopressinOff-label local injection. Vasostrict is supplied as a 20 units/mL concentrate for dilution and as premixed IV products at 0.2–1 units/mL; its label gives no local-infiltration preparation. Published local concentrations include roughly 0.05–0.3 units/mL as well as 0.5 units/mL (20 units total) in a robotic myomectomy cardiac-arrest report; one vaginal hysterectomy RCT used 8 units total. These regimens do not establish a safe local concentration or dose.[7][12][13][17]~120 mL mean reduction in a mixed hysterectomy meta-analysis[6]Serious CV events can occur even with dilute solutions[6][11]
Lidocaine + epinephrineStandard local-anesthetic concentrationsAnalgesia + vasoconstrictionUsed in some colpocleisis techniques[3]; calculate cumulative lidocaine exposure and LAST risk from all local anesthetics. The Xylocaine label contraindicates lidocaine in patients with amide-local-anesthetic hypersensitivity and warns that epinephrine solutions contain metabisulfite, which can trigger allergic reactions in susceptible patients.[18] For otherwise healthy adults, the Xylocaine with epinephrine label recommends no more than 7 mg/kg lidocaine and generally no more than 500 mg. If lidocaine is used for a paracervical block, the label limits it to 200 mg total per 90 minutes and directs slow injection with five minutes between sides; use any lower patient- or procedure-specific limit.[18]

A review included 9 RCTs (903 participants); its vasoconstrictor meta-analysis of six RCTs (491 participants) found vasoconstrictive agents (vasopressin or ornipressin) reduced blood loss by an overall about 70 mL (95% CI −125 to −14) versus placebo or saline, with substantial heterogeneity in dose and technique.[10] For POP surgery specifically, the 2025 Cochrane review pooled two RCTs (146 women) and estimated 28.46 mL less blood loss with vasoconstrictors than with saline (95% CI 22.47–34.45 mL less; moderate-certainty evidence), a difference the authors judged unlikely to be clinically relevant.[1]

Vasopressin​

The most studied agent, given by intracervical or pericervical injection. A meta-analysis of 7 hysterectomy RCTs (455 patients overall; 6 RCTs contributing blood-loss data) showed a mean blood-loss reduction of 119.85 mL; a double-blind RCT (117 women) confirmed lower EBL (312 versus 446 mL, p = 0.006) and a smaller hemoglobin drop with no statistically detected increase in pelvic infection (1.6% versus 7.3%).[6][8] It has the most vaginal-surgery trial evidence among these agents, and serious cardiovascular events after local injection have been reported; comparative cardiovascular risk remains unknown.[6][10][11]

Ornipressin (Por-8)​

A synthetic vasopressin analogue with a more selective V1 profile. An ornipressin vaginal-prolapse RCT (80 randomized; 76 analyzed, 5 IU/100 mL, 80 mL per compartment) cut median blood loss from 81 to 35 mL (p = 0.03) with no significant difference in median pre/postoperative blood pressure or pulse. Availability is jurisdiction-specific.[5]

Epinephrine (adrenaline)​

Epinephrine 1:200,000 has been studied as part of a bupivacaine injectate for vaginal hysterectomy. A 2025 multicentre randomized trial recruited 156 women to receive bupivacaine plus epinephrine or saline; the combination produced 110 mL less estimated blood loss (p < 0.001) and smaller increases in same-day and next-day pain scores, with no detected difference in hemoglobin or postoperative analgesia.[19] An older randomized study of vaginal or laparoscopically assisted vaginal hysterectomy found less bleeding with local epinephrine than terlipressin, but more hypertensive reactions and mild arrhythmias.[20] In a 60-patient laparoscopic myomectomy RCT, dilute vasopressin and epinephrine had similar blood loss; transient BP and HR increases occurred with epinephrine in 13% versus 0% with vasopressin (p = 0.112).[9] The lidocaine-with-epinephrine label (1:200,000 = 5 µg/mL) advises cautious, carefully circumscribed quantities in areas supplied by end arteries or with compromised blood supply, where ischemic injury or necrosis may result.[18] It also warns of arrhythmias when vasoconstrictor-containing solutions are used during or after potent general anesthesia.[18] Do not extrapolate vaginal infiltration practice to penile blocks, digits, compromised flaps or other end-artery fields; use the relevant procedure and local-anesthetic safety guidance.

Head-to-head summary​

VasopressinOrnipressinEpinephrine 1:200,000
CV observationsBradycardia, ischemia and cardiac arrest reportedNo significant median pre/postoperative BP or pulse difference; mean intraoperative systolic and diastolic BP was higher with ornipressin in the 76 analyzed women[5][21]BP/HR changes and arrhythmia risk depend on exposure
Rare-event certaintySerious case reports—Standard dilution does not eliminate systemic risk
AvailabilityWide (some countries restrict)Not in USUS-labeled injectable formulations[18]
Evidence in vaginal surgeryMultiple vaginal RCTs; one mixed-route hysterectomy meta-analysis and one vaginal-surgery meta-analysis pooling vasopressin/ornipressin[6][10]Single RCT (80 randomized; 76 analyzed)[5]Vaginal hysterectomy RCTs (see the cited Epinephrine section)[19][20]

Choose according to procedure, cardiovascular risk, availability and the agreed anesthesia and pharmacy protocol; modest blood-loss changes must be weighed against rare serious harms.[5][6][10]

Cardiovascular Safety — Vasopressin​

The dominant safety concern is vasopressin. Serious events (bradycardia, myocardial ischemia, and cardiac arrest) have been reported even at low concentrations, with cardiac arrest occurring within about 2 minutes of injection in one case report and immediately after injection of 11 units (0.2 units/mL) in another, but the mechanisms were not established; the robotic report considered systemic absorption and positional bradycardia.[11][12][13] Practical precautions:[11][14]

  • Aspirate and inject incrementally; a negative aspiration does not exclude intravascular injection or rapid absorption.
  • Use the lowest effective exposure in a defined local protocol. The label indication for vasopressin is IV use in vasodilatory shock, so local infiltration is off-label; a 0.2 units/mL, 11-unit injection caused arrest in a healthy patient, so neither that concentration nor any published total dose is a validated safety threshold.[13][17]
  • Tell the anesthesia team before injecting; have atropine and resuscitation equipment ready.
  • Cardiovascular risk. The Vasostrict IV label notes that vasopressin may decrease cardiac index and lists myocardial ischemia among reported adverse reactions; consider this when selecting an off-label local agent for patients with cardiovascular disease.[17] ACOG’s hysteroscopy opinion recommends cautious cervical vasoconstrictor administration, especially in office settings, because rare serious cardiovascular events have been reported; it gives no colporrhaphy dose.[14]

Does Hydrodissection Harm the Repair Plane?​

A recurring worry is that ballooning the submucosa "floats" the fibromuscular layer ("pubocervical fascia," not a true anatomic fascia) off where the surgeon needs it. The small Schwarzman RCT measured a histological surrogate: no difference in loose connective tissue at the surgical margin was detected with versus without hydrodissection (13.6% versus 27.3%, p = 0.46); long-term anatomical and functional outcomes were not assessed.[2] The practical caveat is volume: over-injection, especially in atrophic postmenopausal tissue, can distort planes and make the correct layer harder to find.

Adjacent Considerations​

  • Vaginal microcirculation. In an exploratory study of 10 women undergoing native-tissue anterior or posterior colporrhaphy with saline and 1:200,000 epinephrine infiltration, incident dark-field imaging found absent or reduced surgical-site microvascular flow in some participants 1 day after surgery and restored perfusion in all participants at 6 weeks.[15] Mesh exposure and prolapse recurrence were not measured.[15]
  • Practice variation. A Dutch survey of 133 gynecologists found wide variation in whether and how hydrodissection is used during anterior colporrhaphy.[16]

Practical Pearls​

  • Saline alone is an option. It can facilitate dissection; adding a vasoconstrictor is an individualized decision.[1]
  • Incremental injection, limited exposure, communication with anesthesia whenever vasopressin is used.[11]
  • Inject to balloon, not to flood. Enough to define the plane; excess distorts it, worst in atrophic tissue.
  • Match agent to procedure and patient. Local analgesia, fluid volume and vasoconstriction are separate choices.

See Also​

References​

1. Shahid U, Haya N, Baessler K, et al. Perioperative interventions in pelvic organ prolapse surgery. Cochrane Database Syst Rev. 2025;7:CD013105. doi:10.1002/14651858.CD013105.pub2

2. Schwarzman P, Samueli B, Shaco-Levy R, et al. The role of hydrodissection in native tissue repair of anterior vaginal wall defects. Aust N Z J Obstet Gynaecol. 2022;62(1):98–103. doi:10.1111/ajo.13431

3. Raju R, Occhino JA, Linder BJ. LeFort partial colpocleisis: tips and technique. Int Urogynecol J. 2020;31(8):1697–1699. doi:10.1007/s00192-019-04194-3

4. Linder BJ, Gebhart JB, Occhino JA. Total colpocleisis: technical considerations. Int Urogynecol J. 2016;27(11):1767–1769. doi:10.1007/s00192-016-3034-4

5. Henn EW, Nondabula T, Juul L. Effect of vaginal infiltration with ornipressin or saline on intraoperative blood loss during vaginal prolapse surgery: a randomised controlled trial. Int Urogynecol J. 2016;27(3):407–412. doi:10.1007/s00192-015-2821-7

6. Hafidh B, Latifah HM, Gari A, et al. Vasopressin to control blood loss during hysterectomy: a systematic review and meta-analysis of randomized controlled trials. J Minim Invasive Gynecol. 2022;29(3):355–364.e2. doi:10.1016/j.jmig.2021.10.003

7. Ascher-Walsh CJ, Capes T, Smith J, Michels A. Cervical vasopressin compared with no premedication and blood loss during vaginal hysterectomy: a randomized controlled trial. Obstet Gynecol. 2009;113(2 Pt 1):313–318. doi:10.1097/AOG.0b013e3181954c44

8. Kammerer-Doak DN, Rogers RG, Johnson Maybach J, Traynor Mickelson M. Vasopressin as an etiologic factor for infection in gynecologic surgery: a randomized double-blind placebo-controlled trial. Am J Obstet Gynecol. 2001;185(6):1344–1347. doi:10.1067/mob.2001.119076

9. Song T, Kim MK, Kim ML, et al. Use of vasopressin vs epinephrine to reduce haemorrhage during myomectomy: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015;195:177–181. doi:10.1016/j.ejogrb.2015.10.003

10. Cui Y, Chen I, Chernoff A, Clancy A. Effectiveness of prophylactic pharmacological hemostatic agents for reduction of blood loss at vaginal surgery: a systematic review and meta-analysis. Int Urogynecol J. 2023;34(12):2945–2957. doi:10.1007/s00192-023-05614-1

11. Chudnoff S, Glazer S, Levie M. Review of vasopressin use in gynecologic surgery. J Minim Invasive Gynecol. 2012;19(4):422–433. doi:10.1016/j.jmig.2012.03.022

12. Lee GG, Baek SY, Woo Kim T, et al. Cardiac arrest caused by intramyometrial injection of vasopressin during a robotic-assisted laparoscopic myomectomy. J Int Med Res. 2018;46(12):5303–5308. doi:10.1177/0300060518805596

13. Hobo R, Netsu S, Koyasu Y, Tsutsumi O. Bradycardia and cardiac arrest caused by intramyometrial injection of vasopressin during a laparoscopically assisted myomectomy. Obstet Gynecol. 2009;113(2 Pt 2):484–486. doi:10.1097/AOG.0b013e318187e795

14. Committee on Gynecologic Practice. The use of hysteroscopy for the diagnosis and treatment of intrauterine pathology: ACOG Committee Opinion No. 800. Obstet Gynecol. 2020;135(3):e138–e148. doi:10.1097/AOG.0000000000003712

15. Kastelein AW, Diedrich CM, de Waal L, Ince C, Roovers JWR. The vaginal microcirculation after prolapse surgery. Neurourol Urodyn. 2020;39(1):331–338. doi:10.1002/nau.24203

16. Lensen EJ, Stoutjesdijk JA, Withagen MI, Kluivers KB, Vierhout ME. Technique of anterior colporrhaphy: a Dutch evaluation. Int Urogynecol J. 2011;22(5):557–561. doi:10.1007/s00192-010-1353-4

17. Vasostrict (vasopressin) injection. Prescribing information. Par Health USA. DailyMed, revised 2026. dailymed.nlm.nih.gov

18. Xylocaine (lidocaine HCl and epinephrine) injection. Prescribing information. Henry Schein listing. DailyMed, 2025. dailymed.nlm.nih.gov

19. Thiagamoorthy G, Dua A, Araklitis G, et al. "Post-Operative Pain After Pelvic Organ Prolapse Surgery (POPPOP): A Double Blind Randomised Multicentre Study to Assess the Effect of Local Anaesthesia During Vaginal Hysterectomy." BJOG. 2025;132(9):1212–1219. doi:10.1111/1471-0528.18162

20. Bartos P, Popelka P, Adamcová P, Struppl D. "Adrenalin versus terlipressin: blood loss and cardiovascular side-effects in the vaginal part of laparoscopically-assisted vaginal hysterectomy or vaginal hysterectomy." Clin Exp Obstet Gynecol. 2000;27(3-4):182–184. PMID:11214945

21. Haya N, Feiner B, Baessler K, et al. "Perioperative interventions in pelvic organ prolapse surgery." Cochrane Database Syst Rev. 2018;8:CD013105. doi:10.1002/14651858.CD013105

22. Campagna G, Panico G, Morciano A, et al. Vaginal mesh repair systems for pelvic organ prolapse: anatomical study comparing transobturator/transgluteal versus single-incision techniques. Neurourol Urodyn. 2018;37(3):1024–1030. doi:10.1002/nau.23387